LakeShore Biopharma Co., Ltd

NasdaqCM:LSB Stok Raporu

Piyasa değeri: US$41.2m

LakeShore Biopharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

LakeShore Biopharma's earnings have been declining at an average annual rate of -45.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 15% per year.

Anahtar bilgiler

-45.1%

Kazanç büyüme oranı

-15.3%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı15.0%
Özkaynak getirisi-74.1%
Net Marj-75.6%
Son Kazanç Güncellemesi31 Mar 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66%

Nov 01
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66%

LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough

Jun 25
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough

Little Excitement Around YS Biopharma Co., Ltd.'s (NASDAQ:YS) Revenues

May 08
Little Excitement Around YS Biopharma Co., Ltd.'s (NASDAQ:YS) Revenues

Gelir ve Gider Dağılımı

LakeShore Biopharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:LSB Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 24573-433435303
31 Dec 23544-334427342
30 Sep 23561-309373374
30 Jun 23658-195363349
31 Mar 23687-145339319
31 Dec 22698-95370265
30 Sep 22633-72350211
30 Jun 22574-103317219
31 Mar 22503-106279211
31 Mar 21257-19222594

Kaliteli Kazançlar: LSB is currently unprofitable.

Büyüyen Kar Marjı: LSB is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: Insufficient data to determine if LSB's year-on-year earnings growth rate was positive over the past 5 years.

Büyüme Hızlandırma: Unable to compare LSB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: LSB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: LSB has a negative Return on Equity (-74.07%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin